The EMA grants orphan drug designation for Sucampo Pharmaceuticals' (SCMP) retinitis pigmentosa...


The EMA grants orphan drug designation for Sucampo Pharmaceuticals' (SCMP) retinitis pigmentosa treatment unoprostone isopropyl. The FDA has already given the product the same designation and an alternate formulation is FDA approved. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs